This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment-emergent hepatic injury or dysfunction
Timeframe: Up to 30 days after termination of the index treatment
Treatment-emergent renal failure or dysfunction
Timeframe: Up to 30 days after termination of the index treatment
Rehospitalization for the parenteral treatment of fungal infections
Timeframe: Up to 30 days after termination of the index treatment
Death from hepatocellular carcinoma (HCC)
Timeframe: Up to 13 years after treatment